15-day Paxlovid regimen safe but adds no clear long-COVID be

15-day Paxlovid regimen safe but adds no clear long-COVID benefit

A clinical trial led by Stanford Medicine researchers has found that a 15-day course of Paxlovid, an antiviral drug targeting the virus that causes

Related Keywords

Rupinder Singh , Pfizer , Stanford Medicine , Viral Reservoir , Significant Difference ,

© 2025 Vimarsana